Premium
Epidermal growth factor elevates the activity levels of glycolipid sulfotransferases in renal‐cell‐carcinoma cells
Author(s) -
Kobayashi Takahiko,
Honke Koichi,
Gasa Shinsei,
Kato Naoyuki,
Makita Akira,
Miyazaki Tamotsu
Publication year - 1993
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910550321
Subject(s) - sulfotransferase , epidermal growth factor , cell culture , endocrinology , cell growth , medicine , biology , glycolipid , growth factor , receptor , chemistry , biochemistry , sulfation , genetics
Accumulation of sulfoglycolipids associated with markedly elevated levels of glycolipid‐sulfotransferase activity was previously demonstrated in human renal‐cell‐carcinoma cells. To elucidate the regulatory mechanisms of sulfoglycolipid metabolism in renal‐cell carcinoma, effects of various growth factors on the sulfotransferase‐activity levels were investigated using a human renal‐cell‐carcinoma cell line, SMKT‐R3. Exogenous epidermal growth factor (EGF) significantly increased the activity levels of the sulfotransferases in a dose‐dependent manner, but did not change that of arylsulfatase A, which hydrolyzes sulfoglycolipids. Furthermore, metabolic labeling with 35 S‐sulfate revealed that the addition of EGF to the culture medium of the cells resulted in an increment of sulfoglycolipid synthesis. The expression of the EGF receptor on SMKT‐R3 cells was demonstrated by affinity cross‐linking with 125 l‐EGF. These observations suggest that EGF can regulate sulfotransferase‐activity levels in renal‐cell‐carcinoma cells, and function as one of the regulatory factors of sulfoglycolipid synthesis in these carcinoma cells.